On April 13, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) called for a temporary pause in the administration of Johnson & Johnson’s COVID-19 vaccine. As of April 12, approximately 6.8 million doses of this vaccine had been administered in the United States. The pause comes after six cases of a rare blood clot disorder, known as venous sinus thrombosis (CVST), occurred in female patients between the ages of 18 and 48 who received this vaccine.
While the CDC and FDA conduct their investigation of potential adverse events, NPs and other providers will be vaccinating patients using the two other approved COVID-19 vaccines. Patients are strongly encouraged to receive their vaccine as soon as it is available to them. Vaccination against COVID-19 remains the best tool to protect ourselves and loved ones from COVID-19 and is a critical step toward ensuring the health and safety of our communities.